Interaction of recombinant interleukin-2 with liposomal bilayers

被引:23
|
作者
Koppenhagen, FJ
Visser, AJWG
Herron, JN
Storm, G
Crommelin, DJA
机构
[1] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, NL-3508 TB Utrecht, Netherlands
[2] Wageningen Univ Agr, Dept Biomol Sci, Microspect Ctr, Wageningen, Netherlands
[3] Univ Utah, Dept Pharmaceut & Pharmaceut Chem, Salt Lake City, UT USA
关键词
D O I
10.1021/js9704386
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Liposomes have been employed as a delivery system for recombinant interleukin-2 (rIL-2) in cancer immunotherapy. in this study the effects of the rIL-2-bilayer interaction on protein structure were investigated. It was shown that rIL-2 adsorbs to liposomal membranes when added to preformed liposomes. Polarized fluorescence decay studies showed that the single tryptophan in "native" rIL-2 has a relatively large motional freedom, although iodide quenching of this residue's fluorescence was relatively ineffective. However, adsorption of rIL-2 to liposomes alters this situation dramatically-fluorescence intensity increased 2-fold and the residue became more susceptible to iodide quenching. At the same time, the average fluorescence lifetime of the fluorophore is extended. interestingly, circular dichroism studies showed that no major conformational changes occurred in rIL-2's secondary structure upon adsorption. These observations support the hypothesis that intramolecular quenching takes place in the native rIL-2 molecule, which is abrogated upon adsorption to the liposomal membrane, resulting in a higher fluorescence intensity. Fluorescence anisotropy decay experiments indicate that the protein forms self-aggregates under the [ow-ionic strength conditions used, confirming the earlier observations on the tendency or the protein to precipitate in salt-containing media.
引用
收藏
页码:707 / 714
页数:8
相关论文
共 50 条
  • [1] INTERLEUKIN-2-CONTAINING LIPOSOMES - INTERACTION OF INTERLEUKIN-2 WITH LIPOSOMAL BILAYERS AND PRELIMINARY STUDIES ON APPLICATION IN CANCER VACCINES
    BERGERS, JJ
    DENOTTER, W
    DULLENS, HFJ
    KERKVLIET, CTM
    CROMMELIN, DJA
    PHARMACEUTICAL RESEARCH, 1993, 10 (12) : 1715 - 1721
  • [2] RECOMBINANT INTERLEUKIN-2
    BRUTON, JK
    KOELLER, JM
    PHARMACOTHERAPY, 1994, 14 (06): : 635 - 656
  • [3] ACTIVITY OF LIPOSOMAL INTERLEUKIN-2 INVITRO
    ADIBZADEH, M
    WEDER, HG
    REHBEIN, A
    SCHWULERA, U
    OBERMEIER, J
    PAWELEC, G
    MOLECULAR BIOTHERAPY, 1992, 4 (01) : 24 - 28
  • [4] The promise of recombinant interleukin-2
    Moldawer, N
    Carr, E
    AMERICAN JOURNAL OF NURSING, 2000, 100 (05) : 35 - 38
  • [5] BIOTINYLATED RECOMBINANT INTERLEUKIN-2 - A TOOL FOR RESEARCH ON THE INTERLEUKIN-2 RECEPTOR
    FOXWELL, BMJ
    TAYLOR, D
    GREINER, B
    MIHATSCH, MJ
    OLIVIERI, V
    RYFFEL, B
    JOURNAL OF IMMUNOLOGICAL METHODS, 1988, 113 (02) : 221 - 229
  • [6] MODULATION OF THE EXPRESSION OF INTERLEUKIN-2 RECEPTORS OF HUMAN THYMOCYTES BY RECOMBINANT INTERLEUKIN-2
    REEM, GH
    YEH, NH
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1985, 239 (02) : 455 - 461
  • [7] Formulation of liposomes associated with recombinant interleukin-2: effect on interleukin-2 activity
    Pellequer, Y
    Ollivon, M
    Barratt, G
    BIOMEDICINE & PHARMACOTHERAPY, 2004, 58 (03) : 162 - 167
  • [8] OLIGOMERIC FORMS OF RECOMBINANT INTERLEUKIN-2
    MERIIN, AB
    IVANYUSHINA, VA
    KISELEV, OI
    BIOCHEMISTRY-MOSCOW, 1991, 56 (10) : 1294 - 1299
  • [9] CRYSTALLIZATION OF RECOMBINANT HUMAN INTERLEUKIN-2
    MORIYA, N
    YAMADA, T
    KATO, K
    NISHIMURA, O
    BIO-TECHNOLOGY, 1986, 4 (10): : 904 - 905
  • [10] CHEMICAL GLYCOSYLATION OF RECOMBINANT INTERLEUKIN-2
    SABESAN, S
    LINNA, TJ
    NEOGLYCOCONJUGATES, PT A, 1994, 242 : 46 - 56